Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation
| Autor: | Yoshikuni Kawaguchi, Norihiro Kokudo, Shuichiro Shiina, Simone Famularo, Tomoaki Ichikawa, Masatoshi Kudo, Kiyoshi Hasegawa, Shoji Kubo, Yasuhiro Hagiwara, Takamichi Murakami, Namiki Izumi, Tadatoshi Takayama, Yutaka Matsuyama, Takashi Kokudo, Ryosuke Tateishi, Jean Nicolas Vauthey, Andrea Ruzzenente, Michiie Sakamoto, Elena Panettieri, Felice Giuliante, Mario De Bellis, Fabrizio Romano, Osamu Nakashima, Luciano De Carlis, Alfredo Guglielmi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Carcinoma Hepatocellular medicine.medical_treatment Catheter ablation Resection Japan medicine Carcinoma Combined Modality Therapy Hepatectomy Humans Chemoembolization Therapeutic Survival rate Aged Hepatology business.industry Liver Neoplasms Gastroenterology Hepatocellular medicine.disease Ablation Prognosis digestive system diseases Tumor Burden Survival Rate Cohort Catheter Ablation Chemoembolization Female Radiology Therapeutic business |
| Zdroj: | The American journal of gastroenterology. 116(8) |
| ISSN: | 1572-0241 |
| Popis: | INTRODUCTION Most studies predicting survival after resection, transarterial chemoembolization (TACE), and ablation analyzed diameter and number of hepatocellular carcinomas (HCCs) as dichotomous variables, resulting in an underestimation of risk variation. We aimed to develop and validate a new prognostic model for patients with HCC using largest diameter and number of HCCs as continuous variables. METHODS The prognostic model was developed using data from patients undergoing resection, TACE, and ablation in 645 Japanese institutions. The model results were shown after balanced using the inverse probability of treatment-weighted analysis and were externally validated in an international multi-institution cohort. RESULTS Of 77,268 patients, 43,904 patients, including 15,313 (34.9%) undergoing liver resection, 13,375 (30.5%) undergoing TACE, and 15,216 (34.7%) undergoing ablation, met the inclusion criteria. Our model (http://www.u-tokyo-hbp-transplant-surgery.jp/about/calculation.html) showed that the 5-year overall survival (OS) in patients with HCC undergoing these procedures decreased with progressive incremental increases in diameter and number of HCCs. For patients undergoing resection, the inverse probability of treatment-weighted-adjusted 5-year OS probabilities were 10%-20% higher compared with patients undergoing TACE for 1-6 HCC lesions |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|